For Financial Professionals in the US

Agustin Mohedas, Ph.D.

Research Analyst

Agustin Mohedas, Ph.D. is a Research Analyst at Janus Henderson Investors focused primarily on stocks in the biotechnology sector, a position he has held since 2019. Before joining the firm, Dr. Mohedas was a senior analyst at Eventide Asset Management, working on the Healthcare and Life Sciences Fund from 2017. Prior to this, he was an analyst with RA Capital Management, a long/short hedge fund focused on biotechnology, from 2014.

Dr. Mohedas received his bachelor of science degree in biomedical engineering from Texas A&M University, graduating summa cum laude. He also earned a Ph.D. in medical engineering and medical physics from the Harvard-MIT Program in Health Sciences and Technology. His Ph.D. research focused on drug development for a rare genetic disease, resulting in multiple patents and publications. He has 7 years of financial industry experience.

Articles Written

Understanding the Impact of Delta

Understanding the Impact of Delta

The highly infectious variant of COVID-19 has led to rising case numbers, but we explain why a return to normalcy is still within striking distance.

Biopharma’s Targeted Approach to Growth
Quick Views Healthcare

Biopharma’s Targeted Approach to Growth

A new drug targeting a common mutation found in tumors represents a breakthrough in cancer therapy and a potential new source of growth for biopharma.

COVID Variants: The Impact on Pandemic Trajectory, Biopharma Stocks

COVID Variants: The Impact on Pandemic Trajectory, Biopharma Stocks

Making sense of the latest developments around COVID-19 variants and what investors should consider now.

What Will It Take to Reopen the Global Economy?

What Will It Take to Reopen the Global Economy?

In this latest installment of our video series exploring the scientific and investment implications of COVID-19, Portfolio Manager Andy Acker and Biotech Analyst Agustin Mohedas discuss lessons learned as economies reopen, the virus’s fatality rate and the latest news in vaccine development.

COVID-19: Understanding the Science & Investment Implications (Part V)

COVID-19: Understanding the Science & Investment Implications (Part V)

In the latest installment of our series on the scientific and investment implications of COVID-19, Biotech Analyst Agustin Mohedas discusses how efforts to develop treatments and vaccines have accelerated innovation in health care. He also provides insight on the potential impact of certain states reopening their economies and what the timeline to develop an effective vaccine could look like.

COVID-19: Understanding the Science & Investment Implications (Part II)

COVID-19: Understanding the Science & Investment Implications (Part II)

In the second installment of our series on the scientific and investment implications of COVID-19, Biotech Analyst Agustin Mohedas provides insights on how biotech and pharmaceutical companies are responding to the crisis, and why continued systematic testing for the virus is crucial to the eventual reopening and recovery of the U.S. economy.

COVID-19: Understanding the Science & Investment Implications (Part I)

COVID-19: Understanding the Science & Investment Implications (Part I)

In the first of a series on the scientific and investment implications of the coronavirus pandemic, Global Life Sciences Portfolio Manager Andy Acker and Biotech Analyst Agustin Mohedas discuss recent developments to curtail the spread of COVID-19 and how they view the timeline for an eventual return to normalcy in the global economy.